Preview

Пульмонология

Расширенный поиск

Антигистаминные препараты в повседневной практике врача

Полный текст:

Об авторе

О. В. Зайцева
Кафедра детских болезней №1 Российского государственного медицинского университета
Россия


Список литературы

1. Геппе H.A., Карпушкина A.B., Снегоцкая М.H., Васудеван А.К. Антигистаминные препараты в комплексной терапии бронхиальной астмы и аллергического ринита у детей. Рос. педиат. жур., 2000, №2: 55-59.

2. Геппе H.A. Взаимосвязь аллергического ринита и других заболеваний респираторного тракта и роль антигистаминных препаратов в их терапии у детей. В кн. Материалы выездной сессии Российской ассоциации аллергологов и клинических иммунологов. Вейсбаден; 2002. 32.

3. Гущин И.С. Антигистаминные препараты.М.: Алмаз-Пресс; 2000. 55.

4. Ильина Н.И . Аллергический ринит. Consilium Medicuin 2000; 2:(8): 338-344.

5. Ревякина В.А. Современный взгляд на проблему аллергических ринитов у детей. Лечащий врач 2001; 3: 22-27.

6. Ревякина В.А. Эффективность антигистаминного препарата нового поколения Телфаст в лечении детей с аллергическим ринитом. Вопр. соврем, педиатр. 2002; 1 (2): 100-101.

7. Чучалин А.Г. Стратегия профилактики аллергии и бронхиальной астмы. Аллерг. и респир. забол. 2001; 3: 2-5.

8. Anderson H.R., Pottier A.C., Strachan D.P. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. Thorax 1992; 47: 537-542.

9. Baraniuk J.N., Meitzer E.O., Spector S.L. Impact of allergic rhinitis and related airway disorders. J. Respir. Dis. 1996; 17: 11-23.

10. Bernstein D., Schoenwetter W., Nathan R. et at. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 1997; 79: 443-448.

11. Bernstein J.M. The role of IgE-mediated hypersensitivity in the development of otitis media with effusion. Otolaryngol. Clin. N. Am. 1992; 25: 197-211.

12. Bousquet J., Duchateau J., Pignat J.C. et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF36 questionnaire. J. Allergy Clin. Immunol. 1996; 98: 309-316.

13. Bousquet J.,van Cauwenberge P., Khaltaev K. et al. Allergic rhinitis and its impact on asthma (ARIA). Pocket guide. Jeneva: WHO; 2001. 23.

14. Casale T.B., Andrade C., Qu R. Safety and effectiveness of once-daily fexofenadine MCI in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 1999; 20: 193-198.

15. van Cauwenberge P., Juniper E.F. Comparison of efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin. Exp. Allergy 2000; 30: 891-899

16. Corren J., Adinoff A.D., Irvin C.G. Changes in bronchial responsiveness following nasal provocation with allergen. J. Allergy Clin. Immunol. 1992; 89: 611-618.

17. Graft D.F., Bernsein D.A., Goldsobel A. et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann. Allergy. Asthma. Immunol. 2001; 87: 22-26.

18. Hide D.W.; Matthews S., Tariq S. et al. Allergen avoidance in infancy and allergy at 4 years of age. Allergy. 1999; 52: 89-93.

19. Howarth P.H ., Stern M.A., Roi L. et al. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 g once daily) and cetirizine in seasonal allergic rhinitis. J. Allergy Clin. Immunol. 1999; 104: 927-933.

20. Hurst D.S., Venge P. The presence of eosinophil cationic protein in middle ear effusion. Otolaryngol. Head Neck Surg. 1993; 108: 711-722.

21. Hutton N., Wilson M.N., Mellitis E.D. et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized controlled clinical trial. J. Pediatr. 1991; 118: 125-130.

22. Kaiser Ii., Capano D., Harris A. et al. The Claritin Study Group. A double-blind, placebo-controlled comparison of the safety and efficacy of loratadine (Claritin), fexofenadine HCL (Allegra), and placebo in the treatment of subject with seasonal allergic rhinitis (SAR). Allergy 1999; 52: 322.

23. Lippert C., Ling J., Brown A.M . et al. Mass balance and pharmacokinetics of fexofenadine HCL in healthy, male volunteers. Pharmacol. Res. 1995; 12: 390.

24. Lutsky B.N ., Klose P., Melon J. et al. A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 5- years-old children with seasonal allergic rhinitis. Clin. Ther. 1993; 15: 855-865.

25. McConnochie K.M., Roghmann K.J. Bronchiolitis a possible cause of wheezing in childhood: new evidence. Pediatrics 1984; 74: 1-10.

26. Meltzer E.O. Performance effects of antihistamines. J. Allergy Clin Immunol, 1990; 86: 613-619.

27. Newacheck P.W., Stoddard J.J. Prevalence and impact of multiple childhood chronic illnesses. J. Pediatr. 1994; 124: 40-48.

28. Nightingale C.H. Treating allergic rhinitis with second-generation antihistamines Pharmacotherapy 1996; 64: 905-914.

29. Porro E., Calamita P., Rana I. et al. Atopy and environmental factors in upper respiratory infections: an epidemiologieal survey on 2304 school children. Int J. Pediatr. Otorhinolaryngol 1992; 24: 111-120.

30. Pratt C.M., Mason J., Russell T. et al. Cardiovascular safety of fexofenadine HCL. Am. J. Cardiol. 1999; 83: 1451-1454.

31. Russell T., Stoltz М ., Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther. 1998; 64: 612-621.

32. Saarinen U.M., Kajosaari M. Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years. Lancet 1995; 346: 1065-1069.

33. Settipane R., Hagy G.W., Settipane G.A. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994; 15: 21-25.

34. Sheldon L. Spector overview of comorbid associations of allergic rhinitis. J. Allergy Clin. Immunol. 1997; 99: 773-780.

35. Simons F.E., Reggin J.D., Roberts J.R. et al. Benefit risk ratio of antihistamines (H,-receptor antagonists) terfenadine and chlorfeniramine in children. J. Pediatr. 1994; 124: 979-983.

36. Simons F.E., Bergman J.N ., Watson W.T., Simons K.J. The clinical pharmacology of fexofenadine in children. J. Allergy Clin. Immunol. 1996; 98: 1062-1064.

37. Spector S.L ., Nicodemus C., Corren J. et al. Comparison of the bronchodilatory effects on etirizme, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. Ibid. 1995; 96:174-181

38. Watson W.T.A., Becker A.B., Simons P.E.R. Treatment of allergic effect on lower airway responsiveness. Ibid. 1993; 91: 97-101.


Для цитирования:


Зайцева О.В. Антигистаминные препараты в повседневной практике врача. Пульмонология. 2002;(3):107-111.

For citation:


Zaitseva O.V. Anti-histamine drugs in a doctor’s daily practice. PULMONOLOGIYA. 2002;(3):107-111. (In Russ.)

Просмотров: 9


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)